Shihori Tanabe, Ph.D. has been working as a Senior Researcher at the Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences from April 2016. From Apr 2005 until Jan 2006 she held a position of a Post Doctoral Fellow at the Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo. From Feb 2006 until Mar 2010 she worked as a Researcher at the Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Tokyo Japan. She also had a position of a Senior Researcher at the Division of Safety Information on Drug, Food and Chemicals, National Institute of Health Sciences (Apr 2010 - Mar 2016, Tokyo Japan)

• 1. Epithelial-mesenchymal transition and cancer stem cells.-  2. The transcription factors Zeb1 and Snail induce cell malignancy and can-cer stem cell phenotype in prostate cells, increasing androgen synthesis ca-pacity and therapy resistance.- 3. ERBB signaling pathway in cancer stem cells.-  4. Functional and molecular characters of cancer stem cells through devel-opment to establishment.- 5. Microenvironment in cancer stem cells.- 6. Cancer stem cells contribute to drug resistance in multiple different ways.- 7. Abnormal glycosylation in cancer cells and cancer stem cells as a thera-peutic target.

Shihori Tanabe, Ph.D. has been working as a Senior Researcher at the Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences from April 2016. From Apr 2005 until Jan 2006 she held a position of a Post Doctoral Fellow at the Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo. From Feb 2006 until Mar 2010 she worked as a Researcher at the Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Tokyo Japan. She also had a position of a Senior Researcher at the Division of Safety Information on Drug, Food and Chemicals, National Institute of Health Sciences (Apr 2010 - Mar 2016, Tokyo Japan)

• 1. Epithelial-mesenchymal transition and cancer stem cells.-  2. The transcription factors Zeb1 and Snail induce cell malignancy and can-cer stem cell phenotype in prostate cells, increasing androgen synthesis ca-pacity and therapy resistance.- 3. ERBB signaling pathway in cancer stem cells.-  4. Functional and molecular characters of cancer stem cells through devel-opment to establishment.- 5. Microenvironment in cancer stem cells.- 6. Cancer stem cells contribute to drug resistance in multiple different ways.- 7. Abnormal glycosylation in cancer cells and cancer stem cells as a thera-peutic target.

Shihori Tanabe, Ph.D. has been working as a Senior Researcher at the Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences from April 2016. From Apr 2005 until Jan 2006 she held a position of a Post Doctoral Fellow at the Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo. From Feb 2006 until Mar 2010 she worked as a Researcher at the Division of Cellular and Gene Therapy Products, National Institute of Health Sciences, Tokyo Japan. She also had a position of a Senior Researcher at the Division of Safety Information on Drug, Food and Chemicals, National Institute of Health Sciences (Apr 2010 - Mar 2016, Tokyo Japan)

• 1. Epithelial-mesenchymal transition and cancer stem cells.-  2. The transcription factors Zeb1 and Snail induce cell malignancy and can-cer stem cell phenotype in prostate cells, increasing androgen synthesis ca-pacity and therapy resistance.- 3. ERBB signaling pathway in cancer stem cells.-  4. Functional and molecular characters of cancer stem cells through devel-opment to establishment.- 5. Microenvironment in cancer stem cells.- 6. Cancer stem cells contribute to drug resistance in multiple different ways.- 7. Abnormal glycosylation in cancer cells and cancer stem cells as a thera-peutic target.